title: Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer.
abstract: We investigated the activity of a bone-targeting regimen consisting of strontium-89 and doxorubicin in the treatment of patients with androgen-independent prostate cancer. Three and 22 patients with androgen-independent prostate cancer and bone metastasis received doxorubicin at 15 mg/m(2) and 20 mg/m(2), respectively (intravenously by continuous infusion over 24 hours, once per week). All patients received strontium-89 55 μCi/kg, intravenously, every 3 months. Antitumor activity (a prostate specific antigen decrease of ≥75% from baseline) was seen in 32% of evaluable patients. Clinical benefit based on pain relief and performance improvement was achieved in 76% and 40% of patients, respectively. Strontium-89 combined with doxorubicin can be delivered with acceptable toxicities. Strontium-89 combined with doxorubicin is active in the treatment of androgen-independent prostate cancer and may be useful in future studies designed to optimize organ (bone)-specific therapies.
authors.affiliation: Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
authors.forename: S M
authors.initials: SM
authors.lastname: Tu
authors.forename: E S
authors.initials: ES
authors.lastname: Delpassand
authors.forename: D
authors.initials: D
authors.lastname: Jones
authors.forename: R J
authors.initials: RJ
authors.lastname: Amato
authors.forename: J
authors.initials: J
authors.lastname: Ellerhorst
authors.forename: C J
authors.initials: CJ
authors.lastname: Logothetis